Daraxonrasib

Brand names: Rasonque · Active ingredient: Daraxonrasib

In short: RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Forms & strengthsTablets: 100 mg, blue, oval, biconvex, film-coated, debossed with “R” on one side and “100 M” on the other side. Tablets: 150 mg, blue, oval, biconvex, film-coated, debossed with “R” on one side and “150 M” on the other side.
LabelRevolution Medicines, Inc.
Label updatedAug 31, 2026

What is Daraxonrasib used for?

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Daraxonrasib dosage

When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions :

administer a topical corticosteroid (applied to the face and chest) and emollient creams

advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher)

consider prophylactic oral antibiotics (e.g., doxycycline or minocycline)

The recommended dosage of RASONQUE is 300 mg orally once daily until disease progression or unacceptable toxicity.

Take RASONQUE at the same time each day with or without food.

Swallow tablets whole. Do not chew, crush, or split tablets.

If a dose is missed for more than 4 hours, skip the missed dose, and take the next dose at the next regularly scheduled time.

If vomiting occurs after taking the dose, do not take an additional dose. Resume dosing at the next regularly scheduled time.

Recommended dosage reductions for adverse reactions are provided in Table 1. Permanently discontinue RASONQUE in patients who are unable to tolerate 150 mg orally once daily.

Dose Reduction Level | Dosage

First dose reduction | 200 mg once daily

Second dose reduction | 150 mg once daily

Recommended dosage modifications for adverse reactions are provided in Table 2.

Adverse Reaction | SeverityGraded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. | Dosage Modification

Dermatologic Toxicity (rash) | Grade 2 | Consider withholding RASONQUE until recovery to ≤ Grade 1.

Initiate supportive measures, as necessary.

Resume RASONQUE at the same dose level or the next lower dose level.

Grade 3 | Withhold RASONQUE until recovery to ≤ Grade 1.

Initiate supportive measures, as necessary, and consider consultation with a dermatologist.

Resume RASONQUE at the next lower dose level.

Grade 4 | Permanently discontinue.

Stomatitis | Grade 2 | Consider withholding RASONQUE until recovery to ≤ Grade 1.

Initiate supportive measures, as necessary.

Resume RASONQUE at the same dose level or the next lower dose level.

Grade 3 | Withhold RASONQUE until recovery to ≤ Grade 1.

Initiate supportive measures, as necessary.

Resume RASONQUE at the next lower dose level.

Grade 4 | Permanently discontinue.

Diarrhea | Grade 2 | Consider withholding RASONQUE until recovery to ≤ Grade 1.

Initiate antidiarrheal treatment.

Resume RASONQUE at the same dose level or the next lower dose level.

Grade 3 | Withhold RASONQUE until recovery to ≤ Grade 1.

Initiate antidiarrheal treatment.

Resume RASONQUE at the next lower dose level.

Grade 4 | Permanently discontinue.

Gastrointestinal Perforation | Grade 3 | Withhold RASONQUE until recovery to ≤ Grade 1.

If appropriate, resume RASONQUE at the next lower dose level.

Grade 4 | Permanently discontinue. …

How to take Daraxonrasib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Dermatologic Reactions

Advise patients of the risk of dermatologic reactions including rash and to use prophylactic measures. Advise patients to limit sun exposure and contact their healthcare provider if they experience dermatologic reactions .

Stomatitis

Advise patients of the risk of stomatitis. Advise patients to contact their healthcare provider for new onset or worsening stomatitis .

Diarrhea

Advise patients to contact their healthcare provider if they experience new onset or worsening diarrhea .

Gastrointestinal Perforation

Advise patients to contact their healthcare provider immediately if they experience severe abdominal pain or other symptoms of gastrointestinal perforation .

Interstitial Lung Disease (ILD)/Pneumonitis

Advise patients to contact their healthcare provider immediately if they experience new or worsening respiratory symptoms .

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform females of the potential risk to a fetus . …

Warnings & precautions

Do not take this medicine if: None.

RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3. The median time to first onset was 13 days (range: 1 to 106 days). The median time to improvement from Grade 3 to Grade 1 or resolution was 16 days (range: 8 to 218 days). Dermatologic toxicity led to interruption of RASONQUE in 24% of patients, dose reduction in 16% of patients, and dose discontinuation in 0.5% of patients.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity .

RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3. The median time to first onset was 22 days (range: 1 to 343 days). The median time to improvement from Grade 3 to Grade 1 or resolution was 12 days (range: 1 to 127 days). Stomatitis led to interruption of RASONQUE in 17% of patients and dose reduction in 8% of patients.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. …

Daraxonrasib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Dermatologic and Soft Tissue Toxicity

Stomatitis and Oral Disorders

Diarrhea

Gastrointestinal Perforation

Interstitial Lung Disease (ILD)/Pneumonitis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population of RASONQUE described in the WARNINGS AND PRECAUTIONS section reflects exposure to RASONQUE 300 mg once daily in 241 patients with pancreatic adenocarcinoma enrolled in RASolute 302 and 184 patients with pancreatic adenocarcinoma enrolled in the open-label trial RMC-6236-001.

Metastatic Pancreatic Adenocarcinoma

The safety of RASONQUE was evaluated in RASolute 302 . Patients with metastatic pancreatic adenocarcinoma received either RASONQUE 300 mg once daily (N = 241) or physician’s choice of standard of care (SOC) chemotherapy regimens (N = 214). Among patients who received RASONQUE, 52% were exposed for 6 months or longer and 2% were exposed for greater than one year.

Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%). …

Drug interactions

Strong or Moderate CYP3A Inhibitors with or without P-gp Inhibition

Prevention or Management | Strong CYP3A inhibitors with P-glycoprotein (P-gp) inhibition: Avoid concomitant use.

Strong CYP3A inhibitors without P-gp inhibition: Reduce RASONQUE dosage to 150 mg once daily .

Moderate CYP3A inhibitors with P-gp inhibition: Reduce RASONQUE dosage to 100 mg once daily .

Moderate CYP3A inhibitors without P-gp inhibition: Reduce RASONQUE dosage to 200 mg once daily .

Mechanism and Clinical Effect | Daraxonrasib is a CYP3A and P-gp substrate. Moderate or strong CYP3A inhibitors with or without P-gp inhibition increase daraxonrasib exposure , which may increase the risk of adverse reactions.

P-gp Inhibitors

Prevention or Management | Reduce RASONQUE dosage to 150 mg once daily .

Mechanism and Clinical Effect | Daraxonrasib is a P-gp substrate. P-gp inhibitors increase daraxonrasib exposure , which may increase the risk of adverse reactions.

Cyclosporine A

Prevention or Management | Avoid concomitant use of RASONQUE with systemic cyclosporine A or its derivatives.

Mechanism and Clinical Effect | Cyclosporine A or its derivatives and daraxonrasib bind to cyclophilin A. …

About this medicine

Daraxonrasib is an inhibitor of the RAS GTPase family. The molecular formula is C44H58N8O5S and the molecular weight is 811.06 g/mol. The chemical name is Cyclopropanecarboxamide, N-[(2R,14S,18S)-1-ethyl-18,19,20,21-tetrahydro-2-[2-[(1S)-1-methoxyethyl]-5-(4-methyl-1-piperazinyl)-3-pyridinyl]-25,25-dimethyl-15,22-dioxo-17H-5,3-([4,2]-endo-thiazolopropano[1,3]-endo-pyridazinomethanoxypropano)-1H-indol-14-yl]-2-methyl-, (1S,2S)-. Daraxonrasib has the following chemical structure:

Daraxonrasib is a white to yellow crystalline solid; formulated as a spray-dried dispersion (SDD) and incorporated into a tablet for oral use. Daraxonrasib shows a pH-dependent aqueous solubility across the physiological pH range. Daraxonrasib thermodynamic solubility at 24 hours is greater than 10 mg/mL at pH 1.2, while daraxonrasib solubility is approximately 0.009 mg/mL at pH 6.8.

RASONQUE (daraxonrasib) is supplied as film-coated tablets for oral use containing 150 mg or 100 mg of daraxonrasib. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 13a65923-d072-4dac-8620-8eabbf8c3641. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate